04 February 2022

GSK Stockmann advises aTmos Group shareholders on the sale of the group to Ufenau Capital Partners

GSK Stockmann advised the current shareholders of the aTmos Group on the sale of the group to Ufenau Capital Partners.

Headquartered in Riedstadt near Frankfurt, the aTmos Group is a company active throughout Europe in the field of energy-efficient refurbishments of building envelopes for commercial and industrial properties. In addition to modern roof and façade technology, the group also offers industrial ventilation and air conditioning technology as well as control and regulation systems. In addition, aTmos designs and manufactures highly efficient smoke and heat extraction systems under the Bovema Intnerational brand at its own production facility in Heijen, the Netherlands. With over 75 highly qualified employees at seven locations, aTmos serves a large number of high-profile customers in Europe.

The European investor group Ufenau Capital Partners will support the aTmos Group in expanding its strong market position, broadening its range of services and increasing its geographical reach. The current shareholders will assume a stake in the new group as part of the transaction. The group’s management shall remain the same and continue its successful work.

GSK Stockmann and a team led by Markus Söhnchen advised the current shareholders and founders of the aTmos Group on the transaction and the associated private equity and M&A issues.

Advisers to the seller/shareholders of aTmos Group:

GSK Stockmann: Markus Söhnchen (lead, corporate law, PE/M&A), Petra Eckl (tax law), Rainer Werum (real estate law), Martin Hörtz (employment law), Gerhard Gündel (corporate law, M&A, antitrust law), Dominik Berka (tax law); associates: Kristina Riedel, Sarah Lahmer.

Print


Press contact
presse@gsk.de
+49 30 203907-7763

Back

GSK Updates
  • 05 August 2022

    GSK Update: Amendments to the German Act on Evidence of the Essential Working Conditions

    Read more
  • 25 July 2022

    GSK Update: VAT-exempt management of venture capital funds

    Read more
  • 18 July 2022

    GSK Update: AIFMD review: compromises begin to emerge

    Read more
Contact person

Dr. Markus Söhnchen

Partner*

+49 69 71003-0

markus.soehnchen@gsk.de

* Partner: a partner within the meaning of the German Partnership Companies Act.
   Local Partner: not a partner within the meaning of the German Partnership Companies Act.
CO2 Neutral